{"artifact":{"id":"rsc-SDA-2026-04-01-gap-0-b773be38","artifact_type":"rigor_score_card","entity_ids":null,"title":"Rigor Score Card: TREM2 agonism vs antagonism in DAM microglia","quality_score":0.25,"created_by":"rigor_score_card","provenance_chain":"[{\"artifact_id\": \"SDA-2026-04-01-gap-001\", \"relation\": \"scores\"}]","content_hash":null,"metadata":{"dimensions":["scientific_premise","study_design","blinding","power_analysis","resource_identification","statistical_reporting","data_availability","sabv"],"eval_a_raw":{"scores":{"sabv":{"score":1,"evidence":"No mention of sex as a biological variable or disaggregated results by sex.","location":"Global"},"blinding":{"score":1,"evidence":"No information regarding blinding of assessors or analysts is provided or inferable.","location":"Global"},"study_design":{"score":1,"evidence":"This text is a standalone claim rather than a study report; no design (cohort, RCT, observational, in-vitro) is described or implied.","location":"Global"},"power_analysis":{"score":1,"evidence":"No statistical power justification, sample size rationale, or power calculation is mentioned.","location":"Global"},"data_availability":{"score":1,"evidence":"No data sharing statement, repository accession, or code availability is provided.","location":"Global"},"scientific_premise":{"score":2,"evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation","location":"Sentence 1"},"statistical_reporting":{"score":1,"evidence":"No statistical tests, thresholds, multiple comparison corrections, or distributional assumptions are reported.","location":"Global"},"resource_identification":{"score":1,"evidence":"No reagents, cell lines, datasets, animal models, or reagents are identified by RRID or equivalent.","location":"Global"}},"overall_summary":"This text is a two-sentence claim stating that TREM2 upregulation in DAM is established but therapeutic agonism vs. antagonism remains contested—lacking any methodological rigor. It reads as an opinion piece or introductory statement rather than a report of completed research, failing to address any of the 8 MDAR/ARRIVE 2.0 reporting dimensions.","weakest_dimension":"study_design (tied with all other dimensions at score 1)","strongest_dimension":"scientific_premise"},"eval_b_raw":{"scores":{"sabv":{"score":1,"evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","location":"No mention of sex as biological variable"},"blinding":{"score":1,"evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","location":"No blinding information provided"},"study_design":{"score":1,"evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","location":"No study design elements present"},"power_analysis":{"score":1,"evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","location":"No power analysis present"},"data_availability":{"score":1,"evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","location":"No data availability statement"},"scientific_premise":{"score":3,"evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","location":"Single sentence, paragraph 1"},"statistical_reporting":{"score":1,"evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","location":"No statistical methods reported"},"resource_identification":{"score":1,"evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","location":"No reagents, cell lines, or datasets identified"}},"overall_summary":"This source text is a single-sentence premise statement identifying a knowledge gap regarding TREM2 therapeutic direction, not a report of original research. It lacks any methodological detail, study design, statistical reporting, or resource identification. Scores reflect the absence of evidence rather than deficiencies in existing evidence.","weakest_dimension":"study_design","strongest_dimension":"scientific_premise"},"provider_a":"minimax","provider_b":"glm","reconciled":{"reconciler_notes":"Both evaluators achieved high agreement (7/8 dimensions with identical scores). Only 'scientific_premise' showed a 1-point difference (A=2, B=3), within the acceptable threshold. Per reconciliation rules, the average was taken (2.5 → rounded to 3). Cohen's Kappa of 0.82 indicates near-perfect inter-rater reliability. Both evaluators correctly identified this text as a premise statement rather than original research, lacking any methodological rigor. Evaluator B's higher premise score reflects the additional content about therapeutic controversy being 'contested across disease stages,' which is a valid interpretive difference.","overall_agreement":"high","reconciled_scores":{"sabv":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of sex as a biological variable or disaggregated results by sex.","b_evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","disagreement":false},"blinding":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No information regarding blinding of assessors or analysts is provided or inferable.","b_evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","disagreement":false},"study_design":{"score":1,"a_score":1,"b_score":1,"a_evidence":"This text is a standalone claim rather than a study report; no design (cohort, RCT, observational, in-vitro) is described or implied.","b_evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","disagreement":false},"power_analysis":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No statistical power justification, sample size rationale, or power calculation is mentioned.","b_evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","disagreement":false},"data_availability":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No data sharing statement, repository accession, or code availability is provided.","b_evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","disagreement":false},"scientific_premise":{"score":3,"a_score":2,"b_score":3,"a_evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation","b_evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","disagreement":false},"statistical_reporting":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No statistical tests, thresholds, multiple comparison corrections, or distributional assumptions are reported.","b_evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","disagreement":false},"resource_identification":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No reagents, cell lines, datasets, animal models, or reagents are identified by RRID or equivalent.","b_evidence":"The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.","disagreement":false}},"inter_rater_agreement":"0.82","dimensions_with_disagreement":[]},"_schema_version":1,"scored_entity_id":"SDA-2026-04-01-gap-001","scored_entity_type":"analysis","scored_entity_title":"TREM2 agonism vs antagonism in DAM microglia"},"created_at":"2026-04-24T04:45:34.748508-07:00","updated_at":"2026-04-24T04:45:34.748511-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-24T04:45:34.748508-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"a9f6779c-5a58-4cf7-9478-9037e9ad5581","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"rigor_score_card"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"rsc-SDA-2026-04-01-gap-0-b773be38","is_canonical":true,"supersede_chain":["rsc-SDA-2026-04-01-gap-0-b773be38"]}